NCT05112120View on ClinicalTrials.gov

Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

August 3, 2023

Study Completion Date

August 3, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Olumiant

Olumiant (4mg) will be administered in line with standard of care guidance.

Trial Locations (1)

Unknown

NHS GG&C, Glasgow

All Listed Sponsors
collaborator

University of Michigan

OTHER

lead

NHS Greater Glasgow and Clyde

OTHER

NCT05112120 - Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter